Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Riboflavin + dextran is a combination ophthalmic solution used as a photoenhancer in corneal collagen cross-linking (CXL) procedures. The formulation typically contains riboflavin 5’-phosphate (vitamin B2 derivative) at a concentration of approximately 0.1–0.146% and 20% dextran T-500 as an excipient to increase viscosity and maintain corneal structure during the procedure[2][4][8]. Riboflavin acts as a photosensitizer that, when activated by UVA light (370 nm), induces the formation of covalent bonds between collagen fibers in the cornea, thereby increasing its biomechanical strength and halting progression of ectatic disorders such as keratoconus and post-refractive surgery ectasia[4][8]. Dextran serves to control osmolarity and viscosity, ensuring even distribution of riboflavin within the stroma[7]. The most widely used commercial product is Photrexa Viscous. This drug is administered topically during CXL with the KXL System after epithelial debridement[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on riboflavin + dextran.